New hope for Tough-to-Treat esophageal cancer?
NCT ID NCT07446335
Summary
This study aims to see if a new two-drug combination (anlotinib + benmelstobart) works better than the current standard treatment (toripalimab + chemotherapy) for people with advanced esophageal cancer that has specific gene changes. It will involve about 578 adults who have not had prior treatment for their advanced cancer. The main goals are to see which treatment helps patients live longer without their cancer getting worse and which has fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.